Dr Najoua Lalaoui is a Group Leader at the Peter MacCallum Cancer Centre in the Organogenesis Program. She completed her PhD at the University of Burgundy, during which she studied the mechanism of resistance to apoptosis induced by the cytokine TRAIL. In 2010, after being awarded a French ARC postdoctoral Fellowship, she accepted a postdoctoral position at La Trobe University and then at The Walter and Eliza Hall Institute. Her postdoctoral research focused on apoptosis, necroptosis and inflammatory signalling pathways triggered by innate immune ligands. She had a particular interest in determining the role of the TNF regulators RIPK1 and IAP. Her research on IAP inhibitors called Smac-mimetic accelerated their clinical development for the treatment of cancer (Cancer Cell 2016; Cell Death Differentiation 2020). She also revealed new regulatory checkpoints controlling RIPK1 functions (Molecular Cell 2017; Nature 2020).
Throughout her research career, Dr Najoua Lalaoui has constantly secured research funding as a lead investigator through the ‘Association pour la Recherche sur le Cancer’, NHMRC, Cancer Australia and the Worldwide Cancer Research support.
Her laboratory uses various biochemistry, molecular and cellular biology techniques, and mouse models to investigate the causes, consequences and types of cell death activated by the innate immune receptors of the TNF and the TLR families. This fundamental knowledge is applied to reveal novel therapeutic interventions for cancer and inflammatory diseases.
2022 Researcher of the year 2021, Cure Cancer
2021 Innovation Fund Award, WEHI
2021 Burnet Prize, WEHI
2020 Best Institute seminar, WEHI
2019 Innovation Fund Award, WEHI
2018-2022 Victorian Cancer Agency Research Fellowship
2016 Kellaway Award for Excellence in Discovery, WEHI
2016 The Cass Foundation Travel Award
2014 The WEHI Postdoctoral Association Travel Award
2010 Association pour la Recherche sur le Cancer Postdoctoral Fellowship
2009 The Arthritis National Research Foundation Travel Award
2009 Association pour la Recherche sur le Cancer Linkage Scholarship
2005-2008 INSERM Scholarship
2004-2005 Région de Bourgogne Scholarship of merit
Anderton, Chopin, Dawson, Nutt, LALAOUI* and Silke* (2022). Langerhans cells are an essential cellular intermediary in chronic dermatitis. Cell Reports. In press.
Liu, Sandow, Pedrioli, Silke, Hu, Morrish, Chau, Kratina, Kueh, Hottiger, Webb, LALAOUI* and Silke* (2022). Tankyrase-mediated ADP-ribosylation is a novel regulator of TNF-induced cell death. Science Advances. 8, eabh2332.
Liu and LALAOUI (2021). 25 years of research put RIPK1 in the clinic. Seminars in Cell Developmental Biology. 109, 86-95.
LALAOUI, Merino, Giner, Vaillant, Chau, Liu, Kratina, Pal, Whittle, Etemadi, Berthelet, Gräsel, Hall, Ritchie, Ernst, Smyth, Vaux, Visvader, Lindeman, and Silke (2020). Targeting triple-negative breast cancers with the Smac-mimetic birinapant. Cell Death and Differentiation. 27, 2768-80.
LALAOUI*, Boyden*, Oda*, Wood, Stone, Chau, Liu, Stoffels, Kratina, Lawlor, Zaal, Hoffmann, Etemadi, Shield-Artin, Biben, Tsai, Blake, Kuehn, Yang, Anderton, Silke, Wachsmuth, Zheng, Sampaio Moura, Beck, Gutierrez-Cruz, Ombrello, Pinto-Patarroyo, Kueh, Herold, Hall, Wang, Chae, Dmitrieva, McKenzie, Light, Barham, Jones, Romeo, Zhou, Aksentijevich, Mullikin, Gross, Shum, Hawkins, Masters, Lenardo, Boehm, Rosenzweig, Pasparakis, Voss, Gadina, Kastner and Silke (2020). Mutations that prevent caspase-8 cleavage of RIPK1 cause autoinflammatory disease. Nature. 557,103-108.
LALAOUI and Vaux (2018). Recent advances in understanding IAPs. F1000Research. 7. doi: 10.12688/f1000research.16439.1
Anderton, Rickard, Varigos, LALAOUI* and Silke*(2017). IAPs limit RIPK1-mediated skin inflammation. Journal of Investigative Dermatology. 137, 2371-79.
Jaco*, Annibaldi*, LALAOUI*, Wilson, Tenev, Laurien, Kim, Jamal, Wicky John, Liccardi, Chau, Murphy, Brumatti, Feltham, Pasparakis, Silke and Meier (2017). MK2 phosphorylates RIPK1 to prevent TNF-induced cell death. Molecular Cell. 66, 698-710.
LALAOUI and Silke (2017). Jekyll & Hyde: the other life of the death ligand TRAIL. Molecular Cell. 65, 585-87.
LALAOUI and Brumatti (2017). Relevance of necroptosis in cancer. Immunology and Cell Biology. 95, 137-45.
LALAOUI, Hänggi, Brumatti, Chau, Nguyen, Vasilikos, Spilgies, Heckmann, Ma, Ghisi, Salmon, Matthews, de Valle, Moujalled, Menon, Spall, Glaser, Richmond, Lock, Condon, Gugasyan, Gaestel, Guthridge, Johnstone, Munoz, Wei, Ekert, Vaux, Wong and Silke (2016). Targeting p38 or MK2 enhances the anti-leukemic activity of Smac-mimetics. Cancer Cell. 29, 145-58.
LALAOUI, Johnstone and Ekert (2015). Autophagy and AML–food for thought. Cell Death and Differentiation. 23, 5-6.
LALAOUI, Lindqvist, Sandow and Ekert (2015). The molecular relationships between apoptosis, autophagy, and necroptosis. Seminars in Cell Developmental Biology. 39, 63-9.